Melanoma Matters

Summary

In this conversation, Sapna Patel and James Larkin discuss the recent approval of Opdivo Qvantiq, a subcutaneous formulation of nivolumab, and its implications for oncology treatment. They explore the Checkmate 6-7-T study that led to its approval, the efficacy and safety of the new formulation, and the broader regulatory landscape. The discussion also touches on patient perspectives regarding subcutaneous versus intravenous treatment, the potential for future clinical trials, and the importance of patient choice in treatment options.

Keywords

Opdivo, Qvantiq, subcutaneous formulation, oncology, Checkmate 6-7-T, nivolumab, patient experience, regulatory approval, cancer treatment, clinical trials

Takeaways

The approval of Opdivo Qvantiq represents a significant advancement in oncology.

Subcutaneous formulations offer convenience and the possibility of home treatment.

Patient acceptance of subcutaneous treatment is generally high.

The Checkmate 67T study demonstrated the efficacy of subcutaneous nivolumab.

Regulatory approval for subcutaneous formulations is becoming more streamlined.

Patients may value the social interaction of IV treatments over subcutaneous injections.

The future of clinical trials may need to incorporate both subcutaneous and IV options.

Understanding patient preferences is crucial for treatment decisions.

The role of reimbursement in treatment choice cannot be overlooked.

The transition from IV to subcutaneous treatment may impact patient care dynamics.

Titles

Revolutionizing Cancer Treatment: Opdivo Qvantiq

The Future of Subcutaneous Nivolumab

Sound Bites

"It's a no-brainer for patients."

"The FDA has taken a view there."

"This is not just a flu shot."

Chapters

00:00 Why does J have Napoleon on his wall?

05:36 Dreams of new work office furniture...or gym equipment

08:01 CheckMate 67T

19:31 Patient Perspectives on Subcutaneous vs. Intravenous Treatment

27:43 Regulatory and Approval Insights for Opdivo Qvantig

33:30 Future Directions in Clinical Trials

38:02 Fact Check

38:06 Subcutaneous Treatments in Oncology

41:01 Patient Experience and Acceptance of Subcutaneous Treatments

44:17 The Shift in Oncology Patient Interactions

47:06 Current Landscape of Subcutaneous Drugs in Oncology

In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel pick up with Part 2 of 2 - a deep conversation with Claire Turnbull - about the complexities of cancer screening, overdiagnosis, and the role of genetic testing. They explore the implications of screening practices illustrated by the Gilbert Welch paradigm, the challenges faced in patient management, and the future of genetic testing in oncology. The discussion emphasizes the importance of understanding the risks and benefits associated with genetic testing.

Keywords

melanoma, cancer screening, overdiagnosis, genetic testing, patient management, healthcare, public health, cancer research, screening guidelines, cancer predisposition

Takeaways

• The conversation highlights the importance of understanding the value of cancer screening.

• Overdiagnosis is a significant concern in cancer screening practices.

• Genetic testing plays a crucial role in identifying cancer predisposition.

• Screening should be evaluated rigorously to ensure it benefits patients.

• The implications of false positives in screening can lead to unnecessary anxiety for patients.

• Healthcare providers must be responsible for interpreting test results they order.

• The need for genetic counseling is critical in managing test results and patient care.

• There is a growing concern about the overuse of broad genetic testing panels.

• Future advancements in technology may improve screening methods.

• Public health messaging must address the complexities of cancer screening and genetic testing.

Chapters

00:00 Clare Turnbull - Part 2 of 2

04:05 High penetrance, common SNPs, and in betweens

07:15 The Gilbert Welch Paradigm

12:30 Understanding Lead Time and Overdiagnosis

16:11 Randomized Trials in Screening

19:59 Consequences of Screening: Overdiagnosis and Anxiety

22:22 Debate on Screening Protocols and Their Efficacy

25:37 Need for Evidence-Based Genetic Testing

31:19 Ripple Effects of Genetic Testing on Families

34:00 Fact Check

35:47 Genetic testing for ACC?!

36:34 Clinical Genetics clinics are NOT just reading guidelines...

39:52 David Sackett: Evidence-Based Medicine

43:03 Triggering James: (S)he who orders the test reviews & interprets the test

Summary

In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin welcome Clare Turnbull, a clinical geneticist in London, to discuss her journey from studying mathematics to medicine, her work in cancer genetics, and the impact of COVID-19 on healthcare. The conversation explores the role of genetic testing in melanoma, the challenges of public health in cancer treatment, and the ongoing effects of the COVID-19 pandemic on cancer care and patient outcomes.

Keywords

melanoma, genetics, COVID-19, public health, cancer treatment, screening, early detection, healthcare, epidemiology, clinical genetics

Takeaways

Clare Turnbull transitioned from mathematics to medicine in uni,

She has worked extensively in clinical genetics, focusing on cancer genetics.

COVID-19 significantly impacted healthcare delivery and cancer treatment prioritization, the effects of which will take a long time to bear out.

The importance of genetic testing in melanoma is highlighted, for young onset cases or those with a significant family history.

Public health initiatives are crucial for improving cancer outcomes.

The pandemic created a bulge in cancer mortality due to delayed diagnoses.

Screening for melanoma is essential, but the pick-up rates for genetic mutations are low - a cautionary tale.

Sound Bites

"A can-do attitude, what can I do to help?"

"There will be a bulge of mortality."

"The pick-up rate's pretty low."

Chapters

00:00 Opening theme music (My Favourite Dress...The Wedding Present)

00:48 Introduction of Guest Clare Turnbull

03:27 Clare's Journey in Clinical Genetics

05:36 Genomics England, 100K Genomes Project

06:58 Clare's extraordinary efforts during COVID

12:07 Melanoma and genetic risk(s) versus environmental risk

16:28 The Ripple Effects of Genetic Testing on Families

Summary

On mountain emergencies...Sapna's had them, James denies them...This conversation delves into the treatment options available for patients with advanced melanoma who have progressed after anti PD-1 therapy. The discussion covers various clinical studies, response rates, and the implications of combination therapy post-PD1 progression. James and Sapna conclude that while combination therapies show promise, the responses may not be as robust as those seen in frontline treatments.

Keywords

melanoma, PD-1, treatment, clinical trials, immunotherapy, BRAF, response rates, efficacy, combination therapy, patient outcomes

Takeaways

The conversation focuses on treatment options after PD-1 progression.

Clinical studies provide valuable data on post-PD-1 therapies.

Response rates for combination therapies are generally higher than monotherapy.

BRAF status is a critical factor in treatment decisions.

Randomized studies help clarify the efficacy of different treatment approaches.

Combination therapy may offer better outcomes for patients post-PD-1.

Acquired resistance remains a challenge.

Titles

Exploring Treatment Options Beyond PD-1

The Role of Clinical Trials in Melanoma Therapy

Sound Bites

"What to do post PD-1 exposure?"

"Can you get a response to IPI after PD-1?"

"The primary endpoint was PFS, not ORR... "

Chapters

00:00 Opening theme music (My Favourite Dress by The Wedding Present)

01:25 Mountain rescue quickfire

03:08 Post anti-PD1 studies - the issues

04:13 Pires da Silva retrospective study

08:53 Olson single-arm prospective study (and yes we see you Jason)

10:38 SWOG S1616 randomized ph 2 study

16:35 Conclusions

17:17 Fact Check

Summary

In this episode of Melanoma Matters, host Sapna Patel and James Larkin welcome guest Inge Marie Svane to discuss the evolution and future of cancer immunotherapy, particularly focusing on cellular therapy for melanoma. Inge Marie shares her extensive background in the field, the establishment of a cancer immune therapy center in Denmark, and the historical context of cellular therapy. The conversation delves into the current challenges and innovations in T-cell therapy, regulatory hurdles, and the potential for cellular therapy in other solid tumors. The episode highlights the importance of optimizing treatment strategies and the need for collaboration between academia and industry and regulators to improve patient outcomes.

Keywords

melanoma, cancer immunotherapy, cellular therapy, T-cell therapy, checkpoint inhibitors, clinical trials, patient care, regulatory challenges, cancer vaccines, treatment advancements

Takeaways

• Inge Marie Svane has over 25 years of experience in cancer immunotherapy.
• She established a center for cancer immune therapy in Denmark.
• T-cell therapy can benefit patients regardless of checkpoint inhibitor response.
• Not all patients are suitable for T-cell therapy; age and health status matter.
• Optimizing T-cell manufacturing processes is crucial for efficacy.
• Reducing side effects of T-cell therapy is a priority.
• Regulatory frameworks for cellular therapy are challenging in Europe.

• Future strategies may include genetic modifications to enhance T-cell function.
• Cellular therapy shows promise in other solid tumors, but challenges remain.

Titles

Exploring the Future of Melanoma Treatment

Inge Marie Svane on Cancer Immunotherapy Innovations

Sound Bites

"We need to move forward in all directions."

"The system is completely untrained for academia."

Chapters

00:00 Introduction of Guest Inge Marie Svane

05:37 Historical Perspective on Cellular Therapy for Melanoma

09:04 Optimizing T-Cell Therapy: Challenges and Innovations

20:50 Prospects for Cellular Therapy in Other Solid Tumors

Welcome to Season 2!

In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin engage with Michael Atkins from Georgetown University to discuss the advancements in melanoma and kidney cancer treatments, particularly focusing on immunotherapy and cytokine treatments. They explore the groundbreaking DreamSeq trial that compares immunotherapy and targeted therapy in 1L melanoma.

Keywords

melanoma, immunotherapy, cytokines, DreamSeq trial, kidney cancer, cancer treatment, checkpoint inhibitors, complete response, T cells, cancer research

Takeaways

The introduction of checkpoint inhibitors has revolutionized cancer treatment.

Cytokines like IL-2 have a historical role but are being reevaluated in modern therapy.

Complete responses to therapy are crucial for durable benefits in cancer treatment.

The DreamSeq trial highlights the superiority of immunotherapy over targeted therapy in certain patient populations.

Understanding the tumor microenvironment is key to improving immunotherapy outcomes.

The need for better imaging techniques to assess treatment responses is critical.

Aggressive disease patients may require different treatment strategies than those with less aggressive disease.

The importance of patient advocacy in pushing for effective cancer treatments.

Future research should focus on enhancing the efficacy of immunotherapy in various cancers.

Sound Bites

"I love talking about melanoma and immunotherapy."

"Immunotherapy was better in all the subgroups."

"We need to raise the bar above nivo-IPI."

Chapters

00:00 Introduction to Melanoma and Immunotherapy

10:21 The Role of Cytokines in Cancer Treatment

17:02 The DreamSeq Trial Explained

27:20 Comparing Immunotherapy and Targeted Therapy in Kidney Cancer

37:18 Final Thoughts on Immunotherapy's Future

Have you been holding your breath for a new episode? No more holding, time to exhale... and reflect upon 2024. A trailer for you

Time to exhale... and reflect upon 2024.

In this episode, hosts Sapna Patel and James Larkin reflect on their professional and personal experiences from 2024, discussing highlights, lowlights, and the impact of loss in the medical community. They share their intentions and goals for 2025, emphasizing personal bests, leadership , and the importance of friendships. The conversation also touches on cultural reflections, including movies, books, and music, culminating in heartfelt poetry for the New Year.

Keywords

2025 intentions, professional highlights, personal growth, medical community, cultural reflections, leadership challenges, loss, achievements, goals, aspirations

Takeaways

The importance of being in the arena and taking risks.

FDA approval of lifileucel marks a significant milestone.

Loss in the medical community deeply affects personal and professional lives.

Transitioning to new roles can bring self-doubt and challenges.

Celebrating achievements is crucial for personal growth.

Setting intentions for the new year can guide personal and professional goals.

Friendships are foundational to our well-being and happiness.

Looking ahead with optimism.

Titles

Reflections on 2024: Intentions for 2025

Navigating Professional Highlights and Lowlights

Sound Bites

"I want to read the Malcolm Gladwell book."

"Cheers to 2025!"

"It's been one hell of a 365."

Chapters

00:00 2024 Reflections and 2025 Intentions

03:41 Professional Highlights and Lowlights

06:02 Personal Growth and Career Transitions

08:17 Leadership and Self-Doubt

10:44 Memorable Experiences and Connections

12:16 Personal and Professional Intertwining

12:37 Looking Ahead to 2025

17:18 Personal Bests: A Metaphor for Life

18:19 Literary Adventures: Books and Insights

19:07 Cinematic Experiences: Movies of the Year

26:05 Looking Ahead: Goals for 2025

32:06 Reflections and New Year Wishes

33:55 Fact Check

Summary

Favorite holiday songs... perhaps unexpectedly one of our hosts faves is Christmas Card From a Hooker in Minneapolis ... guess which?

In another Best of 2024 episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss key findings from the Society for Melanoma Research (SMR) meeting. They spotlight the TIL for CNS mets study, KEYMAKER U02 Substudy 02D, IMA203, KeyVibe, and the MERLIN 001 study. They emphasize the importance of understanding patient eligibility for clinical trials and the challenges of translating trial results to real-world patient care.

Keywords

melanoma, cellular therapy, brain metastases, clinical trials, treatment efficacy, sentinel lymph node biopsy, immunotherapy, melanoma research, patient care, oncology

Takeaways

• The pilot trial of life elusive cellular therapy shows feasibility and safety.

• Inclusion criteria for clinical trials often exclude real-world patients.

• KEYMAKER U02 Substudy 02D did not demonstrate significant activity in brain metastases.
• IMA203 is a non-surgical cellular therapy trial option for patients with advanced melanoma

• Adjuvant TIGIT plus PD-1 therapy is unlikely to be effective in melanoma (KeyVibe)

• Gene expression tests may not reliably identify patients who can forgo sentinel lymph node biopsies (MERLIN 001).

Chapters

00:00 Festive Greetings and Holiday Tunes

02:44 TIL for CNS Mets

09:04 KEYMAKER U02: Substudy 02D

12:51 IMA203

16:48 KeyVibe

19:27 MERLIN 001

23:28 Happy Holidays!

Summary

Voicing punctuation #2 ...

In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss their second episode in the "Best of 2024" series and review the highlights from the 2024 ESMO Congress. They discuss the final analysis of CheckMate 067, long-term data from KEYNOTE 006, DMFS from NADINA, and the KEYMAKER U02 Substudy 02C. The conversation also covers results from CheckMate 76K and KEYNOTE 716, as well as an exploratory analysis from KEYNOTE 054.

Keywords

ESMO 2024, melanoma, CheckMate 067, KEYNOTE 006, NADINA, KEYMAKER U02, CheckMate 76K, KEYNOTE 716, KEYNOTE 054, immunotherapy

Takeaways

The final analysis of CheckMate 067 shows sustained overall survival benefit and demonstrates cure is possible.

Melanoma-specific survival is becoming a critical endpoint in trials.

Long-term data from KEYNOTE 006 confirms durable benefit of pembrolizumab.

The NADINA study presents sustained event-free survival & DMFS benefits.

KEYMAKER U02 highlights the potential of neoadjuvant platforms.

CheckMate 76K and KEYNOTE 716 show consistent results in adjuvant settings.

The importance of staffing clinical trials for long-term follow-up is emphasized.

New endpoints like PRFS2 are being explored in studies.

Chapters

00:00 Introduction and Holiday Reflections

02:46 Key Presentations from ESMO 2024

03:44 CheckMate 067 Final, 10-Year Analysis

07:38 KEYNOTE 006: 10-Year Data

12:34 NADINA DMFS

16:25 KEYMAKER U02: Substudy 02C (Umbrella Neoadjuvant Arms 4, 5, 6)

21:07 CheckMate 76K & KEYNOTE 716

25:03 KEYNOTE 054: 7 Year Follow-up